Suven Life Sciences Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Suven Life Sciences Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison
Last Updated on: Oct 25, 2026
Key Highlights
The Latest Trading Price of Suven Life Sciences Ltd is ₹ 261.8 as of 23 Oct 15:30
. The P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Suven Life Sciences Ltd changed from ₹ 896.07 crore on March 2021 to ₹ 3503 crore on March 2026 . This represents a CAGR of 25.51% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Suven Life Sciences Ltd for the Jun '26 is ₹ 11.09 crore as compare to the Mar '26 revenue of ₹ 8.3 crore. This represent the growth of 33.61% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Suven Life Sciences Ltd for the Jun '26 is ₹ -124 crore as compare to the Mar '26 ebitda of ₹ -43.86 crore. This represent the growth of 184.95% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Suven Life Sciences Ltd changed from ₹ -28.04 crore to ₹ -127 crore over 9 quarters. This represents a CAGR of 96.11%
The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57%
The Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .
About Suven Life Sciences Ltd
Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989.
The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider.
The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies.
The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.
About Yatharth Hospital & Trauma Care Services Ltd
Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC.
Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care.
The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care
hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.
FAQs for the comparison of Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd
Which company has a larger market capitalization, Suven Life Sciences Ltd or Yatharth Hospital & Trauma Care Services Ltd?
Market cap of Suven Life Sciences Ltd is 7,397 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,978 Cr
What are the key factors driving the stock performance of Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd?
The stock performance of Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd?
As of October 25, 2026, the Suven Life Sciences Ltd stock price is INR ₹261.8. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹931.85.
How do dividend payouts of Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?
To compare the dividend payouts of Suven Life Sciences Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.